HPV, China and Merck

Merck's HPV vaccine gets China approval for men amid declining sales
Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a much-needed boost in a key market where demand has been falling among women.
Merck Gets China Nod on HPV Shot for Men Amid Sales Slump
China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the US drug giant after a rush among women to get the shot lost steam.
Gardasil Gains Ground: Merck's HPV Vaccine for Men Approved in China
Merck's Gardasil vaccine, previously only available to women, has now been approved for men in China. This approval may help Merck overcome declining sales due to weak demand among women and disruptions caused by China's anti-corruption campaign.
Merck’s Gardasil receives expanded approval for males in China
Merck (MRK) announced that the National Medical Products Administration of China approved Gardasil Vaccine for use in males 9-26 years of age
China NMPA grants expanded approval for Merck’s Gardasil for use in males 9-26 years of age to help prevent certain HPV-related cancers & diseases
China NMPA grants expanded approval for Merck’s Gardasil for use in males 9-26 years of age to help prevent certain HPV-related cancers & diseases: Rahway, New Jersey Friday, Ja
China's first HPV vaccine for men approved for market
The HPV vaccine, Gardasil, has gained approval for additional indications from China's National Medical Products Administration, becoming the first and only HPV vaccine authorized for use in men in China,
China administers its first dose of HPV vaccine for men
The recipient in Changsha, the capital of Hunan province, became the first man on the Chinese mainland to receive the HPV vaccine, after US pharmaceutical giant Merck announced its quadrivalent HPV vaccine Gardasil had been approved for additional indications by the National Medical Products Administration.
Merck HPV vaccine for men approved in China
Merck & Co's human papillomavirus (HPV) vaccine, Gardasil, has received approval from China's medical products administration for men aged 9-26 years.Gardasil, a key product for Merck alongside
Merck's HPV Vaccine Gains Ground in China
U.S. drugmaker Merck & Co has received approval in China for its HPV vaccine's use in males, expanding its market reach despite earlier weak sales in the region. This move marks a potential growth opportunity as Gardasil has been key to Merck's market strategy alongside cancer treatment Keytruda.
Merck says HPV vaccine for men approved by China's drug regulator
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration, providing a much-needed boost to the company in a key market.
Hosted on MSN4h
What to Expect From Merck & Co.'s Q4 2024 Earnings Report
With a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare ...
24/7 Wall St. on MSN2d
Merck Just Paid Investors: How Much Did They Receive?
Merck just rewarded its shareholders again with a dividend hike. This Dow stock has come with a quarterly dividend for almost ...
Merck downgraded to Hold from Buy at Truist
Truist downgraded Merck (MRK) to Hold from Buy with a price target of $110, down from $130, as part of a broader research note previewing FY25 ...